pyridostigmine - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.32 [0.13, 0.80]< 10%1 study (1/-)99.3 %some concernnot evaluable moderatecrucial-
deaths 0.33 [0.14, 0.79]< 10%1 study (1/-)99.3 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.33 [0.14, 0.79]< 10%1 study (1/-)99.3 %some concernnot evaluable moderatecrucial-
death or ventilation 0.46 [0.22, 0.96]< 10%1 study (1/-)98.1 %some concernnot evaluable moderateimportant-
hospital discharge 1.13 [0.82, 1.55]> 10%1 study (1/-)77.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.85 [0.27, 2.62]< 10%1 study (1/-)61.3 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.81 [0.27, 2.42]< 10%1 study (1/-)64.7 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.